NAMS · Nasdaq, Nasdaq · CIK 0001936258

NewAmsterdam Pharma Co N.V.

NewAmsterdam Pharma Co N.V.’s most recent SEC filing in our snapshot is a Form 4 filed on Oct 2, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $22.5M and net income of -$203.8M, according to its XBRL data on EDGAR. Its EDGAR record lists 28 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
$22.5M
Net income, FY2025
-$203.8M
Form 4 filings on record, past 12 months
28

Company overview

Legal name (as filed)
NewAmsterdam Pharma Co N.V.
Tickers
NAMS, NAMSW
SEC Central Index Key (CIK)
0001936258
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
NARRDEN, Netherlands
State or country of incorporation
Netherlands
Fiscal year ends
December 31
SEC filer category
Large accelerated filer
Position in SEC ticker list
#1814 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from NewAmsterdam Pharma Co N.V.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
n/aFY2021$102.7MFY2022$14.1MFY2023$45.6MFY2024$22.5MFY2025
Net income
-$41.8MFY2021-$22.6MFY2022-$176.9MFY2023-$241.6MFY2024-$203.8MFY2025
NAMS annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue—$102.7M$14.1M$45.6M$22.5M
Net income-$41.8M-$22.6M-$176.9M-$241.6M-$203.8M
Diluted EPS-$3.81-$1.19-$2.15-$2.56-$1.72
Total assets—$478.5M$347.1M$864.6M$769.3M
Cash and equivalents$53.1M$467.7M$340.4M$771.7M$490.0M

XBRL tags used: revenue = RevenueFromContractWithCustomerExcludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalents. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

NAMS latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Feb 18, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 5, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Sep 29, 20268-KOther events· period Sep 29, 2026Document · Index
May 6, 2026DEF 14ADefinitive proxy statement· period May 6, 2026Document · Index
Mar 31, 202320-FAnnual report of a foreign private issuer· period Dec 31, 2022Document · Index
Nov 13, 20236-KReport of a foreign private issuer· period Nov 13, 2023Document · Index

Recent SEC filings

The 40 newest documents filed by or about NewAmsterdam Pharma Co N.V., by form type:

4 ×118-K ×9144 ×6SCHEDULE 13G/A ×3SCHEDULE 13D/A ×210-Q ×23 ×1144/A ×18-K/A ×1S-8 ×1ARS ×1DEF 14A ×1PRE 14A ×1
NAMS recent filings
FiledFormWhat it isOriginal
Oct 2, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 30, 2026Document · Index
Sep 29, 20268-KOther events· period Sep 29, 2026Document · Index
Sep 22, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Sep 21, 20268-KOther events· period Sep 21, 2026Document · Index
Sep 15, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 14, 2026Document · Index
Sep 9, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 4, 2026Document · Index
Sep 3, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 1, 2026Document · Index
Aug 25, 2026144/A144/ADocument · Index
Aug 25, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 24, 2026Document · Index
Aug 24, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 14, 20268-K/ADirector or officer change· period Jul 16, 2026Document · Index
Aug 14, 20263Initial statement of beneficial ownership· period Aug 10, 2026Document · Index
Aug 14, 20268-KDirector or officer change· period Aug 10, 2026Document · Index
Aug 6, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 5, 20268-KResults of operations· period Aug 5, 2026Document · Index
Aug 5, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Jul 24, 20268-KOther events· period Jul 24, 2026Document · Index
Jul 22, 20268-KDirector or officer change· period Jul 16, 2026Document · Index
Jul 22, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 20, 2026Document · Index
Jun 24, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 22, 2026Document · Index
Jun 5, 2026S-8Registration of employee benefit plan securitiesDocument · Index
Jun 4, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jun 3, 20268-KDirector or officer change; Shareholder vote results· period Jun 2, 2026Document · Index
May 27, 20264Statement of changes in beneficial ownership (insider trade)· period May 26, 2026Document · Index
May 26, 2026144Notice of proposed sale of securitiesDocument · Index
May 14, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
May 7, 20268-KResults of operations· period May 7, 2026Document · Index
May 7, 202610-QQuarterly report· period Mar 31, 2026Document · Index
May 6, 2026ARSARS· period Dec 31, 2025Document · Index
May 6, 2026DEF 14ADefinitive proxy statement· period May 6, 2026Document · Index
May 6, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Apr 24, 20268-KDirector or officer change· period Apr 20, 2026Document · Index
Apr 20, 2026PRE 14APRE 14A· period Apr 20, 2026Document · Index
Mar 12, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 11, 2026Document · Index
Mar 11, 2026144Notice of proposed sale of securitiesDocument · Index
Mar 10, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 6, 2026Document · Index
Mar 9, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 5, 2026Document · Index
Mar 6, 2026144Notice of proposed sale of securitiesDocument · Index
Mar 5, 2026144Notice of proposed sale of securitiesDocument · Index
Mar 2, 2026144Notice of proposed sale of securitiesDocument · Index

Insider filing activity

28 Form 4 filings appear in NewAmsterdam Pharma Co N.V.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001936258 and XBRL company facts. NewAmsterdam Pharma Co N.V. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.